Delving into the Latest Updates on Oxytocin/Ergometrine Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Syntometrine

Target

OXTR x α-adrenergic receptor

Mechanism

OXTR agonists(Oxytocin receptor agonists), α-adrenergic receptor agonists(Alpha adrenergic receptor agonists)

Therapeutic Areas

Urogenital Diseases

Active Indication

Postpartum Hemorrhage

Inactive Indication-

Originator Organization-

Active Organization

Phebra Pty Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (21 Aug 1991),

Postpartum Hemorrhage

Regulation-

Login to view timeline

Structure

Molecular FormulaC66H93N15O18S2

InChIKeyCEDGTLOSFDBJKR-HYFBGPJTSA-N

CAS Registry37209-62-4

Gene Sequence

Sequence Code 124252

In this study the investigators hypothesize that infused combinations of oxytocin and ergometrine will exhibit fewer cardiac and neurological side effects than equipotent infusion of oxytocin alone. In order to perform this study the investigators perform the following steps:
The investigators validate a quantitative measure of uterine tone as our primary endpoint.
The investigators use this endpoint measure in order to determine equipotential doses of different tocotonic drug regimens, based on the ED50 for each.
Using equipontial ratios based on the ED50, the investigators compare hemodynamic and other side effects of these tocotonic drug regimes. Plasma levels of oxytocin will be measured.

Start Date01 Nov 2010

Sponsor / Collaborator

Hadassah University Hospital

NCT00499005 / CompletedPhase 4IIT

Carbetocin Versus Syntometrine for the Third Stage of Labour Following Vaginal Delivery - A Double-blind Randomised Trial

Intramuscular carbetocin is as effective as intramuscular syntometrine for the prevention of postpartum haemorrhage

Start Date01 Nov 2006

Sponsor / Collaborator

National University Hospital

[+1]

100 Clinical Results associated with Oxytocin/Ergometrine Maleate

Login to view more data

100 Translational Medicine associated with Oxytocin/Ergometrine Maleate

Login to view more data

100 Patents (Medical) associated with Oxytocin/Ergometrine Maleate

Login to view more data

88

Literatures (Medical) associated with Oxytocin/Ergometrine Maleate

30 Dec 2022·The Journal of Maternal-Fetal & Neonatal Medicine

Expression of Concern: Carbetocin versus syntometrine for prevention of postpartum hemorrhage after cesarean section

Article

01 Jun 2021·BJOG: An International Journal of Obstetrics & GynaecologyQ1 · MEDICINE

Oxytocin: still the optimal prophylactic despite soaring rates of haemorrhage at birth

Q1 · MEDICINE

Article

Author: Weeks, AD

The results of the IMox study, although not surprising, are very much to be welcomed.This high-quality, double-blind study provides conclusive evidence that there is essentially no difference in effectiveness between the 3 main i.m. (i.m.) prophylactic uterotonics: oxytocin 10IU.Carbetocin and oxytocin + ergometrine (Syntometrine) (van der Nelson et al. BJOG 2021;128:1236-1246).Blood loss of 500 mL, blood loss of 1000 mL and need for blood transfusion were the same in all three groups.The only difference in effectiveness was that those who received oxytocin + ergometrine needed slightly fewer addnl. uterotonics (16%, vs. 19% in the other two groups) suggesting that this combination was marginally stronger.The price for that, however, was great: those who received oxytocin + ergometrine were far more likely to experience nausea (24%), vomiting (18%) or hypertension (12%), and this led to 8% of women feeling that their ability to bond or care for their baby was affected by adverse effects almost twice the rate with oxytocin or carbetocin.All this confirms what we already believed about i.m. uterotonics for prophylaxis: oxytocin alone is the optimal choice.

01 Jun 2021·BJOG: An International Journal of Obstetrics & GynaecologyQ1 · MEDICINE

Intramuscular oxytocin versus Syntometrine^® versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: a randomised double‐blinded clinical trial of effectiveness, side effects and quality of life

Q1 · MEDICINE

Article

Author: Burnard, S ; Alvarez, M ; van der Nelson, H ; Knowlden, J ; Marques, E ; Burden, C ; Mayer, M ; Dailami, N ; O'Brien, S ; Siassakos, D ; Draycott, T ; Winter, C

ObjectiveTo compare intramuscular oxytocin, Syntometrine® and carbetocin for prevention of postpartum haemorrhage after vaginal birth.DesignRandomised double‐blinded clinical trial.SettingSix hospitals in England.PopulationA total of 5929 normotensive women having a singleton vaginal birth.MethodsRandomisation when birth was imminent.Main outcome measuresPrimary: use of additional uterotonic agents. Secondary: weighed blood loss, transfusion, manual removal of placenta, adverse effects, quality of life.ResultsParticipants receiving additional uterotonics: 368 (19.5%) oxytocin, 298 (15.6%) Syntometrine and 364 (19.1%) carbetocin. When pairwise comparisons were made: women receiving carbetocin were significantly more likely to receive additional uterotonics than those receiving Syntometrine (odds ratio [OR] 1.28, 95% CI 1.08–1.51, P = 0.004); the difference between carbetocin and oxytocin was non‐significant (P = 0.78); Participants receiving Syntometrine were significantly less likely to receive additional uterotonics than those receiving oxytocin (OR 0.75, 95% CI 0.65–0.91, P = 0.002). Non‐inferiority between carbetocin and Syntometrine was not shown. Use of Syntometrine reduced non‐drug PPH treatments compared with oxytocin (OR 0.64, 95% CI 0.42–0.97) but not carbetocin (P = 0.64). Rates of PPH and blood transfusion were not different. Syntometrine was associated with an increase in maternal adverse effects and reduced ability of the mother to bond with her baby.ConclusionsNon‐inferiority of carbetocin to Syntometrine was not shown. Carbetocin is not significantly different to oxytocin for use of additional uterotonics. Use of Syntometrine reduced use of additional uterotonics and need for non‐drug PPH treatments compared with oxytocin. Increased maternal adverse effects are a disadvantage of Syntometrine.Tweetable abstractIM carbetocin does not reduce additional uterotonic use compared with IM Syntometrine or oxytocin.

100 Deals associated with Oxytocin/Ergometrine Maleate

Login to view more data